On 17 September 2026, Zhongzhi Pharmaceutical Holdings Limited (ZHONGZHIPHARM) informed registered shareholders that the company’s Interim Report 2026 is now available in both English and Chinese on the official websites of the company (www.zeus.cn) and Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk).

The notification outlines two distribution channels: 1. Electronic delivery: shareholders who provide a valid email address will receive an email alert each time corporate communications are uploaded to the designated websites. 2. Printed notification: shareholders without a valid email address, or those who prefer hard-copy correspondence, will continue to receive printed notices and may request physical copies of any corporate communication free of charge.

To switch to email notifications, shareholders are asked to complete and return the enclosed Reply Form to Union Registrars Limited—ZHONGZHIPHARM’s Hong Kong branch share registrar—either by email (3737-corpcomm@unionregistrars.com.hk), post, or hand delivery to Suites 3301-04, 33/F, Two Chinachem Exchange Square, 338 King’s Road, North Point, Hong Kong. For local mailings, shareholders can use the pre-paid mailing label provided on the Reply Form.

The registrar’s enquiry hotline, (852) 2849 3399, operates Monday to Friday, 9:00 a.m. to 5:00 p.m., excluding Hong Kong public holidays. The notice also reiterates the company’s adherence to Hong Kong’s Personal Data (Privacy) Ordinance regarding the collection, retention and use of shareholders’ personal information.